FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,869,405 | -55.4% | 185,273 | -1.3% | 0.01% | -60.0% |
| Q3 2022 | $4,192,000 | -5.6% | 187,639 | +5.1% | 0.02% | -6.2% |
| Q2 2022 | $4,442,000 | +1.0% | 178,553 | +57.5% | 0.02% | +33.3% |
| Q1 2022 | $4,396,000 | -25.6% | 113,380 | +12.3% | 0.01% | -7.7% |
| Q4 2021 | $5,905,000 | +6.4% | 100,928 | +7.8% | 0.01% | 0.0% |
| Q3 2021 | $5,549,000 | -31.3% | 93,621 | +0.5% | 0.01% | -38.1% |
| Q2 2021 | $8,082,000 | +9.6% | 93,120 | +4.1% | 0.02% | +5.0% |
| Q1 2021 | $7,373,000 | -13.9% | 89,424 | -5.1% | 0.02% | -13.0% |
| Q4 2020 | $8,565,000 | +71.2% | 94,189 | -24.8% | 0.02% | +27.8% |
| Q3 2020 | $5,004,000 | +23.9% | 125,188 | +6.3% | 0.02% | +20.0% |
| Q2 2020 | $4,039,000 | +60.3% | 117,727 | +3.7% | 0.02% | +7.1% |
| Q1 2020 | $2,520,000 | +59.7% | 113,474 | +40.7% | 0.01% | +75.0% |
| Q4 2019 | $1,578,000 | – | 80,651 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $46,987,000 | 60.92% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $278,604,000 | 36.08% |
| Darwin Global Management, Ltd. | 1,370,133 | $112,967,000 | 22.12% |
| Redmile Group, LLC | 12,957,222 | $1,068,323,000 | 15.05% |
| Copernicus Capital Management, LLC | 8,000 | $660,000 | 10.66% |
| Casdin Capital, LLC | 3,400,000 | $280,330,000 | 8.35% |
| Grosvenor Holdings, L.L.C. | 1,123,576 | $92,639,000 | 6.81% |
| DAFNA Capital Management LLC | 314,360 | $25,919,000 | 6.15% |
| Ally Bridge Group (NY) LLC | 270,000 | $22,262,000 | 4.27% |
| Ghost Tree Capital, LLC | 185,000 | $15,253,000 | 3.58% |